Biomarkers of inflammation and repair in kidney disease progression

Puthumana, Jeremy; Thiessen-Philbrook, Heather; Xu, Leyuan; Coca, Steven G.; Garg, Amit X.; Himmelfarb, Jonathan; Bhatraju, Pavan K.; İkizler, T. Alp; Siew, Edward D.; Ware, Lorraine B.; Liu, Kathleen D.; Go, Alan S.; Kaufman, James S.; Kimmel, Paul L.; Chinchilli, Vernon M.; Cantley, Lloyd G.; Parikh, Chirag R.

doi:10.1172/jci139927

Cited by 123 publications

(119 citation statements)

References 38 publications

Supporting

Mentioning

115

Contrasting

Order By: Relevance

“…In this line, an observational study showed that follow-up by a nephrologist was associated with lower long-term all-cause mortality following AKI [137], but implementation in clinical practice would impose a substantial burden on the nephrology community. This calls for risk-stratified follow-up [138], driven by proteinuria [129] and estimated GFR at discharge, potentially aided by biomarker levels [11,56,139].…”

Section: Long-term Outcome Following Akimentioning

confidence: 99%

Acute kidney injury in the critically ill: an updated review on pathophysiology and management

et al. 2021

View full text Add to dashboard Cite

Acute kidney injury (AKI) is now recognized as a heterogeneous syndrome that not only affects acute morbidity and mortality, but also a patient's long-term prognosis. In this narrative review, an update on various aspects of AKI in critically ill patients will be provided. Focus will be on prediction and early detection of AKI (e.g., the role of biomarkers to identify high-risk patients and the use of machine learning to predict AKI), aspects of pathophysiology and progress in the recognition of different phenotypes of AKI, as well as an update on nephrotoxicity and organ cross-talk. In addition, prevention of AKI (focusing on fluid management, kidney perfusion pressure, and the choice of vasopressor) and supportive treatment of AKI is discussed. Finally, post-AKI risk of long-term sequelae including incident or progression of chronic kidney disease, cardiovascular events and mortality, will be addressed.

show abstract

Section: Long-term Outcome Following Akimentioning

confidence: 99%

Acute kidney injury in the critically ill: an updated review on pathophysiology and management

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Urine MCP-1 was independently associated with eGFR decline among hospitalized patients in the ASSESS-AKI cohort (hazard ratio, 1.32 for each doubling; 95% CI 1.18–1.46) [ 15 ], as well as in the SPRINT cohort (adjusted hazard ratio, 2.4; 95% CI 1.1–5.2) [ 16 ]. MCP-1 has also been used to index with another biomarker, urinary epidermal growth factor (EGF; discussed further below).…”

Section: Text Of Reviewmentioning

confidence: 99%

“…In children, population of CKiD cohort, plasma YKL-40 was nominally associated with progression (adjusted hazard ratio 1.33, 95% CI 0.83–2.4), but did not significantly improve the predictive performance of the model, including plasma TNFRs, KIM1 and routinely measured clinical variables [ 11 ▪ ]. Urinary YKL-40 weakly associated with eGFR decline and incident composite renal outcome over time in the hospitalized patients of a multicentre cohort (1.15; 95% CI 1.09–1.22) [ 15 ].…”

Section: Text Of Reviewmentioning

confidence: 99%

Plasma and urine biomarkers in chronic kidney disease: closer to clinical application

Zabetian

Coca

2021

Current Opinion in Nephrology &Amp; Hypertension

Self Cite

View full text Add to dashboard Cite

Purpose of review Chronic kidney disease (CKD) is a silent disease, causing significant health and economic burden worldwide. It is of strong clinical value to identify novel prognostic, predictive, and pharmacodynamic biomarkers of kidney function, as current available measures have limitations. We reviewed the advances in biomarkers in CKD over the preceding year. Recent findings The most frequently studied prognostic plasma biomarkers during recent year were plasma TNFR1, TNFR2, KIM1 and urinary MCP-1 and EGF. New biomarkers such as plasma WFDC2, MMP-7, EFNA4, EPHA2 may also have potential to serve as prognostic biomarkers. There is a shortage of data on biomarkers that are predictive of response to treatments. Data on novel biomarkers to serve as pharmacodynamic biomarkers are limited, but there are emerging data that plasmaTNFR1, TNFR2, KIM-1 are not only prognostic at baseline, but can also contribute to time-updated response signals in response to therapy. Summary Data continue to emerge on applicable biomarkers for prognostic clinical risk stratification, prediction of therapeutic response and assessment of early efficacy of interventions. Although more studies are needed for refinement and specific clinical utility, there seems to be sufficient data to support clinical implementation for some biomarkers.

show abstract

“…Kidney disease progression in COVID-19 is likely multifactorial and might be driven by ongoing inflammation, intrinsic tubular injury or maladaptive repair, among other pathways. Novel kidney-specific plasma and urine biomarkers might help to discern the dominant underlying aetiologies and predict which patients are at highest risk of CKD after COVID-19 hospitalization 7 .…”

mentioning

confidence: 99%